IXICO plc Issue of 590,093 Deferred Consideration Shares (3643T)

TIDMIXI

RNS Number : 3643T

IXICO plc

04 January 2017

4 January 2017

IXICO plc

("IXICO" or the "Company")

Issue of 590,093 Deferred Consideration Shares

IXICO, the brain health company, announces the issue of 590,093 ordinary shares of 1p each as Deferred Consideration in accordance with the terms of the Share Purchase Agreement (the 'Agreement') entered into between the Company and Optimal Medicine Limited on 18 November 2015.

Under the terms of the Agreement, the Deferred Consideration Shares were to be issued on 4 January 2017 following the expiry of the period during which the Company may bring a warranty claim and the determination of the Board of Directors that no such warranty claim is to be made by the Company.

Application has been made for the Deferred Consideration Shares to be admitted to AIM on 9 January 2017. Upon admission of the Deferred Consideration Shares to AIM, the enlarged issued share capital of the Company will be 27,063,284 ordinary shares. The Company does not hold any shares in treasury. Consequently, 27,063,284 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

 
 
  IXICO plc                                     Tel: +44 20 
  Derek Hill, Chief Executive Officer           3763 7499 
  Susan Lowther, Chief Financial Officer 
 
 Shore Capital (Nomad and Broker)             Tel: +44 20 
  Bidhi Bhoma / Edward Mansfield               7408 4090 
 
 FTI Consulting Limited (Investor             Tel: +44 20 
  Relations)                                  3727 1000 
  Simon Conway/Mo Noonan/Matthew Moss

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEEZLFBDFFXBBK

(END) Dow Jones Newswires

January 04, 2017 10:43 ET (15:43 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024